HLA-A*02:07 Allele Associates with Clarithromycin-Induced Cutaneous Adverse Drug Reactions in Chinese Patients

doi:10.1111/bcpt.13011

CORC > 上海药物研究所 > 中国科学院上海药物研究所 > 新药研究国家重点实验室

	*HLA-A02:07 Allele Associates with Clarithromycin-Induced Cutaneous Adverse Drug Reactions in Chinese Patients**
	Chen, Sheng-An 2; Zhang, Li-Rong 3; Yang, Fan-Ping 2; Yang, Lin-Lin 1,3; Yang, Ying4,5 ; Chen, Zi-Hua 2; Jiang, Meng-Lin 4,5; Xiong, Hao 2; Zhu, Hui-Zhong 4,5; Qi, Zheng 4,5
刊名	BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY
	2018-09
卷号	123 期号:3 页码:308-313
ISSN号	1742-7835
DOI	10.1111/bcpt.13011
文献子类	Article
英文摘要	Genetic risk factors could cause cutaneous adverse drug reactions (cADRs) in patients after treatment with clarithromycin. This study explored the association of HLA class I genes with clarithromycin-cADRs in Han Chinese patients. A total of 12 clarithromycin-cADR patients and 34 clarithromycin-tolerant controls were recruited for the high-resolution genotyping of HLA class I genes (HLA-A, HLA-B and HLA-C). The population controls consisted of 283 Han Chinese retrieved from the MHC database for validated comparison. A molecular docking analysis of HLA-A02:07 protein and clarithromycin was conducted using glide module with Schrodinger Suite. Among all tested HLA alleles, the carrier frequencies of HLA-A02:07 (58% versus 5.9%, OR = 22.40, 95% CI = 3.58-139.98, p = 8.20 x 10E-5, pc = 1.1 x 10E-3) and HLA-B46:01 (50% versus 5.9%, OR = 16.00, 95% CI = 2.59-98.99, p = 0.002, pc = 0.03) were significantly higher in clarithromycin-cADRs than in clarithromycin-tolerant controls. However, when compared to population controls, only HLA-A02:07, and not HLA-B46:01, reached statistical significance (58% versus 15.5%, OR = 7.61, 95% CI = 2.31-25.04, p = 1.2 x 10E-4, pc = 1.7 x 10E-3). Furthermore, molecular docking data revealed that clarithromycin could bind to and interact with HLA-A02:07 in two possible binding situations. These data suggest that HLA-A*02:07 might be a genetic risk factor for developing clarithromycin-cADRs in Han Chinese and serve as a useful biomarker for personalized medicine to prevent clarithromycin-cADRs.
资助项目	National Natural Science Foundation of China[81071287] ; National Natural Science Foundation of China[31371274] ; National Key Research and Development Program[2016 YFC0905001] ; Scientific and Technological Research in Open Collaborative Projects of Henan Province[152106000044] ; Shanghai Municipal Commission of Science and Technology Program[14DJ1400100]
WOS关键词	HELICOBACTER-PYLORI INFECTION ; TOXIC EPIDERMAL NECROLYSIS ; STEVENS-JOHNSON SYNDROME ; HYPERSENSITIVITY ; CARBAMAZEPINE ; METAANALYSIS ; HLA ; PHARMACOGENOMICS ; POPULATION ; HAPLOTYPE
WOS研究方向	Pharmacology & Pharmacy ; Toxicology
语种	英语
出版者	WILEY
WOS记录号	WOS:000441237300013
内容类型	期刊论文
源URL	[http://119.78.100.183/handle/2S10ELR8/279602]
专题	新药研究国家重点实验室中科院受体结构与功能重点实验室
通讯作者	Xing, Qing-He; Luo, Xiao-Qun
作者单位	1.Chinese Acad Sci, Drug Discovery & Design Ctr, State Key Lab Drug Res, Shanghai Inst Mat Med, Shanghai, Peoples R China; 2.Fudan Univ, Dept Dermatol, Huashan Hosp, 12 Middle Wulumuqi Rd, Shanghai 200040, Peoples R China; 3.Zhengzhou Univ, Dept Pharmacol, Sch Med, Zhengzhou, Henan, Peoples R China; 4.Fudan Univ, Childrens Hosp, 131 Dong An Rd, Shanghai 200032, Peoples R China; 5.Fudan Univ, Inst Biomed Sci, 131 Dong An Rd, Shanghai 200032, Peoples R China
推荐引用方式 GB/T 7714	Chen, Sheng-An,Zhang, Li-Rong,Yang, Fan-Ping,et al. HLA-A*02:07 Allele Associates with Clarithromycin-Induced Cutaneous Adverse Drug Reactions in Chinese Patients[J]. BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY,2018,123(3):308-313.
APA	Chen, Sheng-An.,Zhang, Li-Rong.,Yang, Fan-Ping.,Yang, Lin-Lin.,Yang, Ying.,...&Luo, Xiao-Qun.(2018).HLA-A*02:07 Allele Associates with Clarithromycin-Induced Cutaneous Adverse Drug Reactions in Chinese Patients.BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY,123(3),308-313.
MLA	Chen, Sheng-An,et al."HLA-A*02:07 Allele Associates with Clarithromycin-Induced Cutaneous Adverse Drug Reactions in Chinese Patients".BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY 123.3(2018):308-313.